AMSTERDAM, The Netherlands , July 12, 2017 (GLOBE NEWSWIRE) — Wright Medical Group N.V. (NASDAQ:WMGI) today announced that it will highlight new innovations at the American Orthopaedic Foot and Ankle Society (AOFAS) 2017 Annual Meeting taking place at the Washington State Convention Center in Seattle, Washington from July 12-15, 2017.
Wright will feature its full range of lower extremities and biologics products at exhibit booth #801 and will showcase, for the first time, three important additions to its foot and ankle portfolio:
INVISION™ Total Ankle Revision System – The first and only system developed specifically for total ankle revision arthroplasty, the INVISION Total Ankle Revision System provides a unique solution for even the most difficult revision procedures. Whether leveraged as a standalone construct or in conjunction with INFINITY and INBONETM components, the INVISION Total Ankle Revision System is an important addition to the continuum of care from total ankle replacement through any necessary revisions. The INVISION Total Ankle Revision System helps surgeons re-build bone lost through previous surgeries and provides modularity to help restore natural joint height.
ORTHOLOC™ 3Di Ankle Fracture Low Profile System – The ORTHOLOC 3Di Ankle Fracture Low Profile System features a complete range of ankle fracture plates designed specifically for the foot and ankle surgeon. The system features low-profile, anatomic plate designs and ORTHOLOC 3Di polyaxial locking screw technology, providing an innovative fracture solution that addresses a primary need for one of the foot and ankle’s largest market segments.
MICA™ Minimally-Invasive Foot & Ankle System – As the first minimally invasive solution specifically designed for foot and ankle surgery, the MICA Minimally-Invasive Foot & Ankle System provides a minimally disruptive, procedurally integrated solution that features specifically designed implants and instrumentation for percutaneous surgery of the foot. The MICA Minimally-Invasive Foot & Ankle System can be used to treat multiple pathologies including one of the most common, Hallux Valgus, commonly known as bunions. Compared to a traditional open surgery, the MICA Minimally-Invasive Foot & Ankle System has been shown to provide less pain, shorter operative times and improved cosmesis.
Robert Palmisano, president and chief executive officer, commented, “We have continued to expand our best-in-class foot and ankle product portfolio to meet the needs of orthopaedic physicians and patients and further extend our leadership position in the fast growing lower extremities and biologics markets. The launch of our unique INVISION Total Ankle Revision System will expand our leadership in total ankle technology and highlights our ability to address the total ankle replacement continuum of care. In addition, the ORTHOLOC 3Di Ankle Fracture Low Profile System and MICA Minimally-Invasive Foot & Ankle System further enhances our offering in the foot and ankle market space and allows for an improved surgical experience.”
Wright is also conducting medical education and training courses during the AOFAS annual meeting in its mobile training lab. These courses will address total ankle arthroplasty, Charcot reconstruction and limb salvage, and ankle and hindfoot fusion using Augment®. More information on Wright Medical’s products can be found at www.wright.com.
Internet Posting of Information
Wright routinely posts information that may be important to investors in the “Investor Relations” section of its website at www.wright.com. The company encourages investors and potential investors to consult the Wright website regularly for important information about Wright.
About Wright Medical Group N.V.
Wright Medical Group N.V. is a global medical device company focused on extremities and biologics products. The company is committed to delivering innovative, value-added solutions improving the quality of life for patients worldwide. Wright is a recognized leader of surgical solutions for the upper extremities (shoulder, elbow, wrist and hand), lower extremities (foot and ankle) and biologics markets, three of the fastest growing segments in orthopaedics. For more information about Wright, visit www.wright.com.
™ and ® denote trademarks and registered trademarks of Wright Medical Group N.V. or its affiliates, registered as indicated in the United States, and in other countries. All other trademarks and trade names referred to in this release are the property of their respective owners.
Cautionary Note Regarding Forward-Looking Statements
This release includes forward-looking statements under the Private Securities Litigation Reform Act of 1995. These forward-looking statements generally can be identified by the use of words such as “anticipate,” “expect,” “intend,” “could,” “may,” “will,” “believe,” “estimate,” “look forward,” “forecast,” “goal,” “target,” “project,” “continue,” “outlook,” “guidance,” “future,” other words of similar meaning and the use of future dates. Forward-looking statements in this release include, but are not limited to, statements about the performance and market acceptance of the company’s products. Forward-looking statements by their nature address matters that are, to different degrees, uncertain. Each forward-looking statement contained in this release is subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statement. Applicable risks and uncertainties include, among others, physician acceptance, endorsement, and use of company products; the effect of regulatory actions, changes in and adoption of reimbursement rates; product liability claims; product recalls; the effects of industry, economic or political conditions outside of the company’s control; competitor activities; and the risks identified under the heading “Risk Factors” in Wright’s Annual Report on Form 10-K for the year ended December 25, 2016 filed by Wright with the SEC on February 23, 2017 and in other subsequent SEC filings by Wright. Investors should not place considerable reliance on the forward-looking statements contained in this release. Investors are encouraged to read Wright’s filings with the SEC, available at www.sec.gov, for a discussion of these and other risks and uncertainties. The forward-looking statements in this release speak only as of the date of this release, and Wright undertakes no obligation to update or revise any of these statements. Wright’s business is subject to substantial risks and uncertainties, including those referenced above. Investors, potential investors, and others should give careful consideration to these risks and uncertainties.
Investors & Media: Julie D. Tracy Sr. Vice President, Chief Communications Officer Wright Medical Group N.V. (901) 290-5817 email@example.com